Report on Landscape of Companies for Influenza Tests (November 2020)

By Halteres Associates

Diagnostics are a fundamental component of successful epidemic and pandemic control strategies. The SARS-CoV-2 pandemic has highlighted on a grand scale the barriers to diagnostic preparedness that are common to all outbreaks, and perhaps has created a unique moment when the commercial, political and technological drive are sufficient to overcome some of these barriers for influenza diagnostics. The landscape of diagnostic developers is enormous, complex, fragmented and constantly evolving, with a variety of players that each has their own mix of products relevant to influenza diagnostics. The aim of the report is to provide clarity around which key players may already have the diagnostic tools that are needed, and which may have innovative technologies, development expertise, or manufacturing and distribution capacity to be able serve as a key partner in ensuring pandemic preparedness.



  • Business and Financial Modeling
  • Business Development
  • Clinical Studies and Regulatory
  • Global Sales and Marketing
  • Impact Modeling and Value Creation
  • Intellectual Property
  • Investor Presentations
  • Market and Technology Assessments
  • Medical Practice
  • Portfolio Planning
  • Product and Process Development
  • Strategic and Tactical Planning


  • Algorithms / Informatics / Health IT
  • Biomarker Discovery and Validation
  • Biostatistics
  • Companion Diagnostics
  • Digital Health and Wellness
  • Histology / Anatomic and Clinical Pathology
  • Immunodiagnostics
  • Instrument Systems
  • Life Science Research Tools
  • Medical Devices
  • Molecular Diagnostics
  • Next Generation Sequencing


  • Blood Screening
  • Chronic Diseases
  • Clinical Laboratory Services
  • Global Health
  • Infectious and Chronic Diseases
  • Life Science Research
  • Oncology
  • “Omics” applications
  • Parasitology
  • Pathology
  • Point of Care Testing
Scroll to Top